Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRAKEN: LY3473329 in Adults With Elevated Lipoprotein(a)
2022-501466-21-00Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in hyperlipoproteinemia and atherosclerotic disease comparing LY3473329 once daily with Placebo once daily (2 arms). Primary endpoint: Percent Change from Baseline in Lipoprotein(a) [Lp(a)]. Started Feb 2023; status: completed.
02
Drugs
muvalaplin
03
Conditions
hyperlipoproteinemiaatherosclerotic disease
Beyond the preview
Go deeper on 2022-501466-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501466-21-00.